2026-01-06 - Analysis Report
Okay, let's break down the analysis of Recursion Pharmaceuticals (RXRX).

**0) Report Structure**

The report will follow this structure:

1.  **Return Rate Comparison:**  Simple numbers, then divergence analysis.
2.  **Moving Averages:**  5-day, 20-day, and 60-day SMAs.
3.  **Index Analysis:** RSI, PPO, Hybrid Signal, Expected Return, and recent divergence changes.
4.  **News & Events:** Summarize key news headlines.
5.  **Earnings Analysis:** Present and analyze quarterly EPS and revenue data.
6.  **Financial Data:** Revenue, Profitability, Equity and ROE.
7.  **Comprehensive Analysis:**  A summary of all findings, integrating different data points.

**1) Return Rate Comparison**

*   **RXRX Cumulative Return:** -31.43%
*   **VOO (S&P 500) Cumulative Return:** 39.85%
*   **Divergence:** Current: -71.3, Relative Divergence: 2.4

**Analysis:** RXRX has significantly underperformed the S&P 500.  The stock's cumulative return is negative, while the S&P 500 has generated a substantial positive return. The divergence shows RXRX's performance is far behind the market benchmark. A relative divergence of 2.4 indicates RXRX is near its minimum divergence range.

**Company Overview:** Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company that combines experimental biology and artificial intelligence to discover, develop, and commercialize novel therapeutics.

**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2022-2024  | 11.0% | 55.8% | -9.0% | 2.3 | 3.7 |
| 2023-2025  | 9.0% | 59.2% | -53.0% | 2.6 | 2.2 |

**Analysis:** The CAGR shows that RXRX returned positive growth over the measured periods. MDD shows a level of risk, with more than 50% reduction during the measured period. The alpha is negative, meaning the stock is underperforming relative to its benchmark. A beta greater than 1 indicates that RXRX is more volatile than the market. A Cap(B) figure is reducing as time passes.

**2) Recent Stock Price Fluctuations**

*   **Current Price:** 4.199999809265137
*   **Last Market Data:**  {'price': 4.37, 'previousClose': 4.2, 'change': 4.05}
*   **5-day SMA:** 4.156
*   **20-day SMA:** 4.431
*   **60-day SMA:** 4.9053

**Analysis:** RXRX's current price is below all three simple moving averages. The recent price increase on the last market day suggests a possible short-term upward trend. The 5-day SMA is below the 20-day and 60-day SMA, indicating a downward trend in the recent past. The large change on the last day indicates volatility.

**3) Index Analysis**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment)
*   **RSI:** 40.10
*   **PPO:** -0.37
*   **Hybrid Signal:** cash\_0% Buy 100% of cash (228 shares - Very Safe - MRI:0.90) Monthly invest 1.7% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** 2.4 (+): 단기상승 (Short-term increase)
*   **Expected Return (%):** -218.4%

**Analysis:** The MRI suggests a medium investment recommendation. The RSI indicates that the stock is not yet oversold, but approaching that level.  The negative PPO suggests the stock is trading below its moving averages. The Hybrid Signal recommends a full investment, citing a very safe profile. The recent increase in relative divergence aligns with the recent price increase. The expected return is very negative, which casts doubt on a long-term investment at this point.

**4) Recent News & Significant Events**

*   **Positive:** Several articles highlight positive developments, including a JPMorgan upgrade and gains in trial data.
*   **Mixed:** One article discusses whether RXRX is a fundamentally strong penny stock.
*   **Neutral:** Nikko Asset Management Americas Inc. Sells Shares of Recursion Pharmaceuticals, Inc.
*   **Valuation Focused:**  One article focuses on assessing the company's valuation after new activist investor filings.

**Summary:** Recent news suggests a mixed sentiment. The J.P. Morgan upgrade and trial data gains are positive. However, the discussion about RXRX being a penny stock suggests high risk. The article on activist investor filings indicates potential changes in the company's direction. The sale of shares by Nikko Asset Management Americas Inc. could signal low expectation.

**4-2) Analyst Opinions**

*   **Mean Rating:** Not provided
*   **Target Price (avg/high/low):** 7.00 / 11.00 / 3.00
*   **Recent Rating Changes:** Not provided

**Analysis:** The average analyst target price is significantly higher than the current price, suggesting upside potential. However, the low target price suggests some analysts are bearish.

**5) Recent Earnings Analysis**

| 날짜       | EPS   | 매출     |
|------------|-------|----------|
| 2025-11-05 | -0.36 | 0.01 B$  |
| 2025-08-05 | -0.41 | 0.02 B$  |
| 2025-05-05 | -0.5  | 0.01 B$  |
| 2024-11-06 | -0.34 | 0.03 B$  |
| 2025-11-05 | -0.34 | 0.03 B$  |

**Analysis:** RXRX is not currently profitable. EPS is consistently negative. Revenue fluctuates, and has mostly decreased over the last few quarters.

**6) Financial Information**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | $0.00B     | -194.74%      |
| 2025-06-30   | $0.02B     | -5.54%        |
| 2025-03-31   | $0.01B     | -47.31%       |
| 2024-12-31   | $0.00B     | -183.62%      |
| 2024-09-30   | $0.03B     | 53.69%        |

| Quarter      | Equity     | ROE       |
|--------------|------------|-----------|
| 2025-09-30   | $1.05B     | -15.50%   |
| 2025-06-30   | $0.92B     | -18.70%   |
| 2025-03-31   | $0.93B     | -21.68%   |
| 2024-12-31   | $1.03B     | -17.29%   |
| 2024-09-30   | $0.52B     | -18.27%   |

**Analysis:** Revenue is inconsistent and often very low. Profit margins are mostly negative, indicating the company is spending significantly more than it earns. The company has large equity, indicating a solid asset base. ROE is negative, meaning the company is not generating profits from its equity.

**7) Comprehensive Analysis**

RXRX has significantly underperformed the S&P 500. While the most recent day showed a positive price change and the MRI indicates a medium investment recommendation, several factors suggest caution. The company is currently unprofitable, with negative EPS and inconsistent revenue. While the company has large equity, the ROE is negative. News sentiment is mixed, with some positive updates offset by concerns about the stock's penny stock status. While analysts have a high target, it is important to consider the current risks.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.